Lung Cancer
1479-0032: Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations
- Details
ClinicalTrials.gov ID:
NCT07195695
Diagnosis Type:
NA
USOR Number:
- Address
,
P: